When Aβ and Tau protein biological standards are used for detection, the best opportunity for early intervention is missed, thus, it is crucial to screen and identify early-stage molecular markers for AD and develop intervention strategies for early diagnosis and treatment of AD. The gene discussed is MAPT; the disease is Alzheimer disease.